Erasca
Erasca is a precision oncology company dedicated to discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Erasca Overview
Erasca Funding Rounds
Round | Date | Amount Raised | Valuation | Investors | Sources |
---|---|---|---|---|---|
IPO | 7/16/2021 | ||||
Series B2 | 1/20/2021 | ||||
Series B | 8/31/2020 | ||||
Series A | 3/5/2019 |
Erasca Investors
Investor | Investment Rounds | Lead Partner | Initial Investment | Other Notable Investments |
---|---|---|---|---|
ARCH Venture Partners | Series B, Series B2, Series A | Series B (2020-08-31) | ||
Andreessen Horowitz | Series A | Series A (2019-03-05) | ||
EDBI | Series B | Series B (2020-08-31) | ||
Evolution VC Partners | Series B | Series B (2020-08-31) | ||
Hillhouse Investment Group | Series B | Series B (2020-08-31) |
Erasca 409a Valuations
Date | Price per share | Est. Valuation | Filling |
---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view |
Erasca Filings
Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Latest Erasca News
The Manufacturers Life Insurance Company Increases Stock Holdings in Erasca, Inc. (NASDAQ:ERAS)
Defense WorldOctober 21, 2024
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth
Simply Wall StOctober 15, 2024
Erasca: New Focus After Restructuring, But Need More Differentiation (NASDAQ:ERAS)
Seeking AlphaSeptember 30, 2024
Marshall Wace LLP Invests $8.67 Million in Erasca, Inc. (NASDAQ:ERAS)
MarketBeatSeptember 30, 2024
Frazier Life Sciences Management L.P. Invests $38.27 Million in Erasca, Inc. (NASDAQ:ERAS)
MarketBeatSeptember 29, 2024
Affinity Asset Advisors LLC Invests $5.90 Million in Erasca, Inc. (NASDAQ:ERAS)
MarketBeatSeptember 25, 2024
Logos Global Management LP Acquires New Shares in Erasca, Inc. (NASDAQ:ERAS)
MarketBeatSeptember 24, 2024
Erasca, Inc.(NasdaqGS: ERAS) added to S&P Biotechnology Select Industry Index
Marketscreener.comSeptember 22, 2024